Generated Narrative: Composition 370502 version: 25; Last updated: 2025-10-21 10:47:22+0000; Language: en Profile: ParticipantFlowReport ArtifactPublicationStatus: Active url: https://fevir.net/resources/Composition/370502 identifier: FEvIR Object Identifier/370502, FEvIR Linking Identifier/NCT03640312-participant-flow-report status: Final type: Participant Flow Report date: 2025-10-21 10:47:22+0000 author: [No author listed.] title: Participant Flow Report for NCT03640312 custodian: Computable Publishing LLC RelatesTos - Type Target[x] * Cite As Participant Flow Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370502. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/370502. Computable resource at: https://fevir.net/resources/Composition/370502#json. Generated Narrative: Group #FG000 Profile: ExposureGroup name: NCT03640312 Flow Group QUARTET LDQT description: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States. QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. type: Person membership: Enumerated quantity: 32 Characteristics - Code Value[x] Exclude * Research Study from which this is a flow group NCT03640312 false Generated Narrative: Group #FG001 Profile: ExposureGroup name: NCT03640312 Flow Group Candesartan description: Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. type: Person membership: Enumerated quantity: 30 Characteristics - Code Value[x] Exclude * Research Study from which this is a flow group NCT03640312 false Generated Narrative: Evidence #NCT03640312-flow-milestone-0-Overall-Study-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-0-Overall-Study-group-FG000 title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: QUARTET LDQT variableDefinition variableRole: Outcome observed: STARTED at Overall Study Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03640312-flow-milestone-0-Overall-Study-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-0-Overall-Study-group-FG001 title: ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Candesartan variableDefinition variableRole: Outcome observed: STARTED at Overall Study Statistics - StatisticType Quantity * Count 30 Generated Narrative: Evidence #NCT03640312-flow-milestone-1-Overall-Study-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-1-Overall-Study-group-FG000 title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: QUARTET LDQT variableDefinition variableRole: Outcome observed: 6 Week Follow Up at Overall Study Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03640312-flow-milestone-1-Overall-Study-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-1-Overall-Study-group-FG001 title: ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Candesartan variableDefinition variableRole: Outcome observed: 6 Week Follow Up at Overall Study Statistics - StatisticType Quantity * Count 28 Generated Narrative: Evidence #NCT03640312-flow-milestone-2-Overall-Study-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-2-Overall-Study-group-FG000 title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: QUARTET LDQT variableDefinition variableRole: Outcome observed: COMPLETED at Overall Study Statistics - StatisticType Quantity * Count 29 Generated Narrative: Evidence #NCT03640312-flow-milestone-2-Overall-Study-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-2-Overall-Study-group-FG001 title: ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Candesartan variableDefinition variableRole: Outcome observed: COMPLETED at Overall Study Statistics - StatisticType Quantity * Count 24 Generated Narrative: Evidence #NCT03640312-flow-milestone-3-Overall-Study-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-3-Overall-Study-group-FG000 title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: QUARTET LDQT variableDefinition variableRole: Outcome observed: NOT COMPLETED at Overall Study Statistics - StatisticType Quantity * Count 3 Generated Narrative: Evidence #NCT03640312-flow-milestone-3-Overall-Study-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-milestone-3-Overall-Study-group-FG001 title: ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Candesartan variableDefinition variableRole: Outcome observed: NOT COMPLETED at Overall Study Statistics - StatisticType Quantity * Count 6 Generated Narrative: Evidence #NCT03640312-flow-reason-Overall-Study-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-reason-Overall-Study-group-FG000 title: ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: QUARTET LDQT variableDefinition variableRole: Outcome observed: Reasons for withdraw at Overall Study Statistics - StatisticType Category Quantity * Count Lost to Follow-up 3 Generated Narrative: Evidence #NCT03640312-flow-reason-Overall-Study-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03640312-flow-reason-Overall-Study-group-FG001 title: ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Candesartan variableDefinition variableRole: Outcome observed: Reasons for withdraw at Overall Study Statistics - StatisticType Category Quantity * Count Lost to Follow-up 6
Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States. QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
Research Study from which this is a flow group
Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study
Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study
ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study
ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study
ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study
ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study
ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study
ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study
ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study
ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study
Participant Flow Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370502. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/370502. Computable resource at: https://fevir.net/resources/Composition/370502#json.
NA - all enrolled participants were randomized.
120 were consented and assessed for eligibility. 58 were excluded for not meeting either inclusion or exclusion criteria, declining participation, or not showing up for randomization visits. Thus, these 58 individuals were not randomized, and 62 participants were randomized
QUARTET LDQT, Candesartan
[No data.]